SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Chen, Yu Wen ^a   Hsiao, Pi Jung ^b   Weng, Ching Chieh ^a   Kuo, Kung Kai ^c   Kuo, Tzu Lei ^a   Wu, Deng Chyang ^b,d   Hung, Wen Chun ^e   Cheng, Kuang Hung ^a  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

CD133; EGFR; Pancreatic cancer; SMAD4 DPC4; TGF 1 pathway

Indexed keywords

CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; PROTEIN KINASE B; SMAD4 PROTEIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULOTROPIN; CISPLATIN; GEFITINIB; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUCIFERASE ASSAY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING; CELL MIGRATION; CHEMOSENSITIVITY; DRUG TARGETING; GENE OVEREXPRESSION; IN VIVO STUDY; PANCREATIC CANCER CELL LINE; PHENOTYPE; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; PANCREATIC NEOPLASMS; PHENOTYPE; SMAD4 PROTEIN;

EID: 84899088025     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-181     Document Type: Article

References (58)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7(3):163-172. 10.1038/nrclinonc.2009.236, 20101258.
2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825. 10.1056/NEJMoa1011923, 21561347, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup.
3. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29(34):4548-54. 10.1200/JCO.2011.36.5742, 3565012, 21969517.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369(18):1691-1703. 10.1056/NEJMoa1304369, 24131140.
5. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. Molecular pathology of pancreatic cancer. Cancer J 2001, 7(4):251-258.
6. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2(12):897-909. 10.1038/nrc949, 12459728.
7. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20(10):1218-1249. 10.1101/gad.1415606, 16702400.
8. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006, 20(22):3130-3146. 10.1101/gad.1478706, 1635148, 17114584.
9. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996, 383(6603):832-836. 10.1038/383832a0, 8893010.
10. Wrana J, Pawson T. Signal transduction. Mad about SMADs. Nature 1997, 388(6637):28-29.
11. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996, 13(3):343-346. 10.1038/ng0796-343, 8673134.
12. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271(5247):350-353. 10.1126/science.271.5247.350, 8553070.
13. Moore PS, Beghelli S, Zamboni G, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer 2003, 2:7. 10.1186/1476-4598-2-7, 149421, 12537585.
14. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002, 62(2):497-505.
15. Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 2008, 29(3):528-535.
16. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 2010, 49(4):342-352. 2921682, 20073072.
17. Kojima K, Vickers SM, Adsay NV, Jhala NC, Kim HG, Schoeb TR, Grizzle WE, Klug CA. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Res 2007, 67(17):8121-8130. 10.1158/0008-5472.CAN-06-4167, 17804724.
18. Singh P, Srinivasan R, Wig JD. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2012, 41(4):541-546. 10.1097/MPA.0b013e318247d6af, 22504380.
19. Singh P, Srinivasan R, Wig JD, Radotra BD. A study of Smad4, Smad6 and Smad7 in Surgically Resected Samples of Pancreatic Ductal Adenocarcinoma and Their Correlation with Clinicopathological Parameters and Patient Survival. BMC Res Notes 2011, 4:560. 10.1186/1756-0500-4-560, 3268768, 22195733.
20. Su HT, Weng CC, Hsiao PJ, Chen LH, Kuo TL, Chen YW, Kuo KK, Cheng KH. Stem Cell Marker Nestin Is Critical for TGF-beta1-Mediated Tumor Progression in Pancreatic Cancer. Mol Cancer Res 2012, 11(7):768-779.
21. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, Zhou JR, Thiagalingam S. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011, 71(3):998-1008. 10.1158/0008-5472.CAN-09-3269, 3075468, 21245094.
22. Chiu CY, Kuo KK, Kuo TL, Lee KT, Cheng KH. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res 2012, 10(3):415-427. 10.1158/1541-7786.MCR-11-0293, 22241220.
23. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005, 102(39):13909-13914. 10.1073/pnas.0506517102, 1236573, 16172383.
24. Zhao S, Wang Y, Cao L, Ouellette MM, Freeman JW. Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer 2010, 127(9):2076-2087. 10.1002/ijc.25412, 2932752, 20473902.
25. Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Lüttges J, Klöppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A 2000, 97(17):9624-9629. 10.1073/pnas.97.17.9624, 16915, 10944227.
26. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002, 20(23):4531-4542. 10.1200/JCO.2002.12.063, 12454109.
27. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009, 15(14):4674-4679. 10.1158/1078-0432.CCR-09-0227, 2819274, 19584151.
28. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002, 109(12):1551-1559. 10.1172/JCI0215234, 151012, 12070302.
29. Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA. EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene 2011, 31(22):2783-2793. 3711644, 21963850.
30. Sunamura M, Lefter LP, Duda DG, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. Pancreas 2004, 28(3):311-316. 10.1097/00006676-200404000-00019, 15084978.
31. Howe JR, Roth S, Ringold JC, Summers RW, Järvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998, 280(5366):1086-1088. 10.1126/science.280.5366.1086, 9582123.
32. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. Cancer Res 1996, 56(11):2527-2530.
33. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004, 64(24):9002-9011. 10.1158/0008-5472.CAN-04-2111, 15604265.
34. Villanueva A, García C, Paules AB, Vicente M, Megías M, Reyes G, de Villalonga P, Agell N, Lluís F, Bachs O, Capellá G. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998, 17(15):1969-1978. 10.1038/sj.onc.1202118, 9788440.
35. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004, 6(5):603-610. 10.1593/neo.04241, 1531665, 15548370.
36. Jadrich JL, O'Connor MB, Coucouvanis E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 2006, 133(8):1529-1541. 10.1242/dev.02333, 16556914.
37. Dai JL, Schutte M, Bansal RK, Wilentz RE, Sugar AY, Kern SE. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog 1999, 26(1):37-43. 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6, 10487520.
38. Volmer MW, Radacz Y, Hahn SA, Klein-Scory S, Stuhler K, Zapatka M, Schmiegel W, Meyer HE, Schwarte-Waldhoff I. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a " secretome" analysis. Proteomics 2004, 4(5):1324-1334. 10.1002/pmic.200300703, 15188399.
39. Schwarte-Waldhoff I, Klein S, Blass-Kampmann S, Hintelmann A, Eilert C, Dreschers S, Kalthoff H, Hahn SA, Schmiegel W. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene 1999, 18(20):3152-3158. 10.1038/sj.onc.1202641, 10340387.
40. Kim S, Domon-Dell C, Kang J, Chung DH, Freund JN, Evers BM. Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J Biol Chem 2004, 279(6):4285-4291.
41. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270(5244):2008-2011. 10.1126/science.270.5244.2008, 8533096.
42. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002, 115(Pt 15):3193-3206.
43. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007, 67(8):3752-3758. 10.1158/0008-5472.CAN-06-3851, 17440088.
44. Weiss C, Faust D, Durk H, Kolluri SK, Pelzer A, Schneider S, Dietrich C, Oesch F, Gottlicher M. TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway. Oncogene 2005, 24(31):4975-4983. 10.1038/sj.onc.1208679, 15897893.
45. Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, Gutkind JS, Coso OA. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J Biol Chem 2005, 280(19):18842-18852. 10.1074/jbc.M500620200, 15708845.
46. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-323. 10.1016/j.stem.2007.06.002, 18371365.
47. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98(8):1389-1397. 10.1038/sj.bjc.6604307, 2361715, 18349830.
48. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003, 11(3):305-309.
49. Perera RM, Bardeesy N. Ready, set, go: the EGF receptor at the pancreatic cancer starting line. Cancer Cell 2012, 22(3):281-282. 10.1016/j.ccr.2012.08.019, 3564545, 22975369.
50. Wei LC, Shi M, Chen LW, Cao R, Zhang P, Chan YS. Nestin-containing cells express glial fibrillary acidic protein in the proliferative regions of central nervous system of postnatal developing and adult mice. Brain Res Dev Brain Res 2002, 139(1):9-17. 10.1016/S0165-3806(02)00509-6, 12414089.
51. Tohyama T, Lee VM, Rorke LB, Marvin M, McKay RD, Trojanowski JQ. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 1992, 66(3):303-313.
52. Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M, Ishiwata T. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 2011, 11(5):512-523. 10.4161/cbt.11.5.14673, 3230315, 21258211.
53. Bünger S, Barow M, Thorns C, Freitag-Wolf S, Danner S, Tiede S, Pries R, Görg S, Bruch HP, Roblick UJ, Kruse C, Habermann JK. Pancreatic carcinoma cell lines reflect frequency and variability of cancer stem cell markers in clinical tissue. Eur Surg Res 2012, 49(2):88-98. 10.1159/000341669, 22948659.
54. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008, 7(4):829-840. 10.1158/1535-7163.MCT-07-0337, 3088432, 18413796.
55. Bartscht T, Lehnert H, Gieseler F, Ungefroren H. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells. Cancer Chemother Pharmacol 2012, 70(2):221-230. 10.1007/s00280-012-1904-0, 22699812.
56. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2008, 2(1):83-95. 2727779, 19707431.
57. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10(7):461-466. 10.1634/theoncologist.10-7-461, 16079312.
58. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008, 14(16):5142-5149. 10.1158/1078-0432.CCR-07-4072, 2699587, 18698032.